On average, analysts expect that Kite Pharma will report full year sales of $9.23 million for the current financial year, with estimates ranging from $26.10 million to $49.80 million. On September 27 Barclays left the company rating at "Equal-weight" and raised the price target from $58.00 to $65.00.
Several hedge funds have recently bought and sold shares of KITE. The rating was downgraded by Standpoint Research to "Hold" on Monday, March 13. Kite Pharma now has an average rating of "Buy" and an average price target of $87.66.
The current consensus rating for Kite Pharma, Inc. Finally, ValuEngine upgraded shares of Kite Pharma from a "sell" rating to a "hold" rating in a research report on Friday, June 2nd. UBS AG cut shares of Kite Pharma from an "outperform" rating to a "market perform" rating in a research report on Monday, May 8th. One analyst has rated the stock with a sell rating, ten have given a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company's stock. On July 6, 2016 Barclays began coverage of KITE with an initial rating of "Equal-weight" and price target of $58.00. "(KITE) Issued By Wedbush" was first posted by BBNS and is the sole property of of BBNS. If you are viewing this report on another site, it was stolen and reposted in violation of United States and global trademark and copyright law. The original version of this story can be read at https://www.com-unik.info/2017/08/09/kite-pharma-inc-nasdaqkite-expected-to-post-quarterly-sales-of-9-23-million.html. Vanguard Group Inc. now owns 3,661,547 shares of the biopharmaceutical company's stock valued at $287,395,000 after buying an additional 507,289 shares in the last quarter. The stock last traded at $119.76 which is marginally over $103.84, the stock's 50 day moving average and which is a tad above the 200 day moving average of $79.27. The stock's market capitalization is 6.79B, it has a 52-week low of 39.82 and a 52-week high of 122.19.
Seth MacFarlane Says He's Sick of Bleak, Dystopian Sci-Fi
Seth MacFarlane is seeking escape from the current wave of dystopian science fiction, and his vehicle is " The Orville ". But The Orville is actually a far cry from Family Guy , much closer to being Star Trek itself than any sort of parody.
Kite Pharma (NASDAQ:KITE) last announced its quarterly earnings data on Monday, May 8th. The biopharmaceutical company reported ($1.94) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($1.40) by $0.54.
Kite Pharma, Inc., launched on June 1, 2009, is a clinical-stage biopharmaceutical company. The firm had revenue of $10.10 million during the quarter, compared to analyst estimates of $9.59 million. During the same period a year ago, the business posted ($0.60) EPS.
A number of other research firms also recently weighed in on KITE. BlackRock Inc. raised its stake in shares of Kite Pharma by 106,272.1% in the first quarter. Six analysts have made estimates for Kite Pharma's earnings, with estimates ranging from $5.20 million to $10.35 million. Finally, Norges Bank acquired a new position in Kite Pharma during the fourth quarter valued at about $16,848,000. LLC now owns 71,160 shares of the biopharmaceutical company's stock valued at $5,585,000 after buying an additional 5,273 shares during the period. Turner Investments LLC acquired a new stake in Kite Pharma during the first quarter valued at about $235,000. Vanguard Group Inc is the second biggest holder with 4 million shares now valued at 287.40 million whilst T. Rowe Price Associates, Inc. has 3 million shares valued at 251.78 million. Winslow Evans & Crocker Inc. bought a new position in shares of Kite Pharma during the second quarter worth about $124,000. First Trust Advisors LP now owns 610,572 shares of the biopharmaceutical company's stock valued at $47,924,000 after buying an additional 3,300 shares in the last quarter. Also, EVP Timothy L. Moore sold 6,000 shares of the firm's stock in a transaction on Thursday, August 3rd. The shares were sold at an average price of $88.55, for a total transaction of $885,500.00. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. The shares were sold at an average price of $107.69, for a total transaction of $1,292,280.00. Following the sale, the chief operating officer now directly owns 132,795 shares of the company's stock, valued at approximately $13,689,836.55. The disclosure for this purchase can be found here. Insiders have sold a total of 165,099 shares of company stock valued at $16,244,448 over the last three months.
- Rep. Darrell Issa talks about ways to stop North Korea's nuclear ambitions
- Up to 50 refugees 'deliberately drowned' off Yemen
- Scotiabank Cuts Ritchie Bros. Auctioneers Inc (RBA) Price Target to C$41.00
- L'ex-pompier Anthony Cliche de nouveau recherché
- Telangana: PV Sindhu's training to start after August 20
- Trump Had A Folder Of Positive News About Himself Delivered Twice Daily
- Is the How I Met Your Mother spin-off actually happening?
- Ashley Judd Describes Being Victim of 'Everyday Sexism' in Airport Security Encounter
- Reviewing nukes was not Trump's first order, it was his 13th
- Disney Ditches Netflix for Own Streaming Service